**Name of journal:** World Journal of Gastroenterology  
**Manuscript NO:** 94529  
**Title:** Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease  
**Provenance and peer review:** Invited manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewers code:** 06076623  
**Position:** Peer Reviewer  
**Academic degree:** PhD  
**Professional title:** Research Associate  
**Reviewer’s Country/Territory:** China  
**Author’s Country/Territory:** Egypt  
**Manuscript submission date:** 2024-03-20  
**Reviewer chosen by:** Yu Bai  
**Reviewer accepted review:** 2024-03-27 08:49  
**Reviewer performed review:** 2024-04-02 02:07  
**Review time:** 5 Days and 17 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No novelty</td>
<td></td>
</tr>
<tr>
<td>Creativity or innovation of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No creativity or innovation</td>
<td></td>
</tr>
</tbody>
</table>
**SPECIFIC COMMENTS TO AUTHORS**
Very good article. The authors provide a good description and summary of the pathogenesis and lifestyle interventions for NAFLD, which is consistent with what has been known and what has been researched in recent years. It is worth noting that the statement "there has not an approved specific medical treatment for this health problem" is inaccurate, because the FDA has already approved Rezdiffra as a drug for the treatment of NAFLD/NASH, which is a milestone in the field of liver disease. It is hoped that the authors can make appropriate modifications to this statement. This manuscript is suitable for publication in the World Journal of Gastroenterology.